IQ Consortium

Organization of pharmaceutical and biotechnology companies with a mission of advancing science and technology.

#PBPK

PBBM Report Template: Considerations for Improved Quality in View of Regulatory Submissions

by

Sponsored by the Regulatory Advisory Committee

Pharmaceutical innovators and generic companies employ Physiologically Based Biopharmaceutics Models (PBBMs) to inform drug product development and may be able to waive clinical pharmacokinetic studies for changes occurring both before and after product approval. The 2023 M-CERSI workshop titled “PBBM Best Practices for Drug Product Quality: Regulatory and Industry Perspectives” recognized that a standardized PBBM report template could benefit both industry stakeholders and regulatory bodies. This webinar will discuss the PBBM report template, which summarizes a set of expectations and proposes a structure for presenting input data, modeling plan, context of the model, model parameters, and clinical data on which the model was developed and validated to minimize the number of PBBM rejections in the future. Efforts have been made to align the framework presented in the PBBM report template with the overarching ICH M15 Guideline on Model Informed Drug Development (MIDD).

For further information about the PBBM report template, please refer to the publication Arora et al. Development of a Physiologically Based Biopharmaceutics Model (PBBM) Report Template: Considerations for Improved Quality in View of Regulatory Submissions. Molecular Pharmaceutics (submission in progress)

Making Bitter Medicines Better for Everyone

by

* New Date*

Presented by the Pediatric Working Group
Sponsored by the Drug Product Leadership Group

People vary widely in how bitter they perceive medicines to be, which can impact how easily they take them. A global study from the Monell Chemical Senses Center found that genetic ancestry influences how bitter certain medicines taste and how well sweeteners or other modifiers reduce bitterness. For example, a common sweetener worked better for some groups than others, which has important implications for making medicines more palatable for children and adults alike. By understanding these differences, pharmaceutical companies can develop better formulations that improve medication adherence, particularly in pediatric and global health settings where taking every dose is critical.

Predictive Dissolution Models for Surrogate Release: An Industry Position

by

*New Date!*

Presented by: IQ Dissolution Working Group
Sponsored by: IQ Drug Product Leadership Group

In vitro dissolution testing is commonly performed to ensure that oral solid dosage medicines are of high quality and will achieve their targeted in vivo performance. However, this testing is time and material-consuming. Therefore, pharmaceutical companies have been developing predictive dissolution models (PDMs) for drug product release based on fast at- and/or on-line measurements. Recently, PDMs have seen acceptance by major regulatory bodies as release tests for the dissolution critical quality attribute.

This webinar will describe several methodologies to develop and validate a fit-for-purpose model, then to implement it as a surrogate release test for dissolution. These approaches will be exemplified by real-life case studies, which demonstrate that PDMs for release are not only viable but more sustainable than in vitro dissolution testing and can significantly accelerate drug product release. The rise of continuous manufacturing within the pharmaceutical industry further favors the implementation of real-time release testing. Therefore, a steep uptake of PDMs for release is expected once this methodology is globally accepted. To that end, it is advantageous for global regulators and pharmaceutical innovators to coalesce around a harmonized set of expectations for the development, validation, implementation, and lifecycle of PDMs as part of drug product release testing.

SPEAKERS/MODERATORS

  • Tessa Carducci, PhD, Merck & Co., Inc.
  • Melanie Dumarey, PhD, AstraZeneca
  • Himanshu Gandhi, Bristol-Myers Squibb
  • Sarah Nielsen, PhD, Johnson & Johnson
  • Yanmei Lan, PhD, Takeda
  • Ana Filipa Tavares da Silva, PhD, Janssen Pharmaceutica NV
  • Nikolay Zaborenko, PhD, Eli Lilly & Co.

 

Attendance is limited. Register today!

This is a public webinar. Membership in IQ Consortium is not required to attend.

Best Industry Practices for the Qualification of Food Vehicles in Drug Administration

by Leave a Comment

Presented by the Pediatric Working Group
Sponsored by the Drug Product Leadership Group

Speakers: Anna Externbrink, MSD and and Yemin Liu, AbbVie
Moderator: Elizabeth Galella, Bristol Myers Squibb

The use of soft foods and liquids as vehicles for drug administration can significantly enhance palatability and acceptability in pediatric patients, thereby improving therapeutic outcomes. In vitro assessments are employed to identify and qualify food vehicles for drug product labeling; however, interpreting and applying regulatory guidance in this area can be challenging.

This webinar aims to provide pharmaceutical R&D professionals and regulators with a scientific framework for justifying food vehicles in drug administration while facilitating the development of clear and meaningful label instructions. Attendees will gain insights into best industry practices, supported by case studies and practical examples.

This is a public webinar. Membership in the IQ Consortium is not required to attend.